(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, chemotherapy, EGFR, FLAURA2, lung cancer, osimertinib, Susan Galbraith, Tagrisso, Treatment USA
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer. The company is aiming to have an AstraZeneca medicine for over half of all … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, FLAURA2, IASLC Conference 2023, Lung Cancer Treatments, Susan Galbraith, Tagrisso (osimertinib), therapy, World Conference on Lung Cancer (WCLC)
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
